Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.61 |
| ▸ | NPC1 | O15118 | 8/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | HPGD | P15428 | 6/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1608448 | 0.85 | NPC1 (0.57) | RAB9ANPC1KMT2AKDM4EALDH1A1 | |
| SCHEMBL1249937 | 0.80 | MAPT (0.60) | RAB9ANPC1KMT2AKDM4EALDH1A1 | |
| SCHEMBL13004548 | 0.78 | NPC1 (0.85) | RAB9ANPC1KMT2AKDM4EALDH1A1 | |
| SCHEMBL16675218 | 0.77 | NPC1 (0.76) | RAB9ANPC1KMT2AKDM4EALDH1A1 | |
| SCHEMBL3188390 | 0.76 | APP (0.60) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL17877090 | 0.74 | NPC1 (0.96) | RAB9ANPC1KMT2AKDM4EALDH1A1 | |
| SCHEMBL29121418 | 0.72 | RAB9A (1.00) | RAB9ANPC1KMT2AKDM4EALDH1A1 | |
| SCHEMBL2360960 | 0.72 | NPC1 (0.73) | RAB9ANPC1KMT2AKDM4EALDH1A1 | |
| SCHEMBL16407493 | 0.71 | NPC1 (0.90) | RAB9ANPC1KMT2AKDM4EALDH1A1 | |
| SCHEMBL16407501 | 0.71 | NPC1 (0.90) | RAB9ANPC1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110081297-A1 | Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles | MERCK & CO. INC. | 2011-04-07 | — | — | US | claimed |
| WO-2009146343-A1 | NOVEL SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES | MERCK & CO., INC. (US) | 2009-12-03 | — | — | WO | claimed |
| US-20110081297-A1 | Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles | MERCK & CO. INC. | 2011-04-07 | — | — | US | disclosed |
| US-20110081297-A1 | Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles | MERCK & CO. INC. | 2011-04-07 | — | — | US | disclosed |
| US-20110081297-A1 | Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles | MERCK & CO. INC. | 2011-04-07 | — | — | US | disclosed |
| WO-2009146343-A1 | NOVEL SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES | MERCK & CO., INC. (US) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110081297-A1 | Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles | APP, PSEN1, BACE1 | RAB9A 4026/4885NPC1 129/4885KMT2A 4317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.